Series of gain-of-function experiments showed that ectopic expression of ZMYND8 followed by doxorubicin treatment in MDA-MB-231 cells led to significant regression in bCSC (CD44+/CD24−) content along with a decrease in expression of other stemness markers, ALDH1 and ESA (Fig. 5d–e and Supplementary Fig. 8a–d), consequently manifesting a compromised mammosphere formation (Fig. 5f, g) and migratory potential (Fig. 5h, i) of the cancer cells. Here, CD24 is linked to cancer.